Simulations Plus Acquires Pro-ficiency For $100M, Expanding Reach Across Drug Development Spectrum
Author: Benzinga Newsdesk | June 12, 2024 08:02am
The transaction expands Simulations Plus' presence across the drug development continuum from establishing pre-clinical protocols to product commercialization, providing pharmaceutical and biotech companies with an end-to-end offering that now includes clinical trial operations, medical affairs and commercial market launches. Pro-ficiency's suite of software and services, developed with AI technologies, is a highly complementary and synergistic addition to Simulations Plus' platform by expanding its capabilities to enhance clinical trial and launch training, data analytics and outcomes.
Posted In: SLP